The invention relates probes for detecting and/or quantifying double-stranded DNA. The invention particularly relates to luminescence based intercalating probes, and methods of using such probes to detect or quantify double-stranded DNA.
Detection of DNA and RNA is fundamental for diagnosing and preventing infectious diseases caused by pathogens, such as viruses and bacteria. The benchmark for DNA detection is the polymerase chain reaction (PCR), which is based on the rapid generation of large amounts of identical copies from a single fragment of target DNA.
PCR relies on the binding of short DNA primers that bind to the target DNA after which a DNA polymerase enzyme generates new DNA fragments based on the target template. To this end, PCR requires three distinct thermal cycling steps in which the temperature of the reaction mixture is varied between 50-98° C. To monitor and quantify the DNA during PCR, intercalating dye molecules are used that exhibit a large increase in fluorescence when binding to DNA. The fluorescent signal is generated using an optical excitation source such as a laser or LED, after which the intensity of the collected light is used as a measure for DNA concentration. Although quantitative PCR (qPCR) has been shown to allow highly sensitive detection of DNA, the required set-up can be prohibitive in situations where the use of expensive, specialized equipment (containing lasers, optics and a temperature controller) is limited or undesirable, for example in point-of-care diagnostic testing. Additionally, fluorescence suffers from a high background signal, which can pose a problem when performing measurements in complex media such as patient blood.
In order to reduce the complexity of PCR-based detection strategies and move towards point-of-care applications, several alternative approaches have been investigated. A well-established strategy is to use isothermal nucleic acid amplification methods that allow for amplification at constant temperatures, eliminating the need for thermal cycling equipment. Two examples that have received attention recently are the SHERLOCK and DETECTR platforms, that combine isothermal amplification with CRISPR-associated (Cas) proteins that are capable of recognizing highly specific DNA or RNA sequences (Gootenberg, J. S. et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 356, 438-442 (2017); Chen, J. S. et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 360, 436-439 (2018)). The SHERLOCK method uses isothermal amplification via recombinase polymerase amplification (RPA), which relies on a set of three enzymes for binding of primers and subsequent DNA amplification. It can be performed at a constant temperature of 37-42° C., obviating the need for thermal cycling. Similarly, DETECTR uses loop-mediated isothermal amplification (LAMP), which is performed at a constant temperature of 60-65° C. and is based on a set of specifically designed looped primers that facilitate the amplification cycle. For both SHERLOCK and DETECTR, a fluorescent output signal is generated upon binding of the Cas proteins to single-stranded RNA and double-stranded DNA, respectively, and subsequent cleavage of single-stranded nucleic acid reporters containing a fluorophore and quencher pair. For point-of-care applications, a colorimetric alternative to the fluorescent readout was realized and incorporated into a lateral flow assay (Patchsung, M. et al. Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. Nat. Biomed. Eng. 4, 1140-1149 (2020)). Although these assays successfully combine isothermal amplification with specific and ultrasensitive detection of viral nucleic acid sources, they still rely on a fluorescent readout that requires an external excitation source or lateral flow strips, which typically only provide qualitative information.
Sensors based on bioluminescence represent a powerful alternative strategy to fluorescent detection. By employing bioluminescent luciferase enzymes that produce light without requiring external excitation, it is possible to circumvent high background signals and the use of specialized optical instrumentation for detection. Such bioluminescent proteins can be coupled to an acceptor to enable bioluminescent resonance energy transfer (BRET), similar to the more commonly used FRET-based approaches. This principle has already been employed to create analogues of fluorescent detection methods, including bioluminescent molecular beacons, which consist of a luciferase and acceptor dye connected to a DNA hairpin. The hairpin initially brings both components into close proximity, facilitating BRET, but separates the two in complexation with target ssDNA or ssRNA (Engelen, W., van de Wiel, K. M., Meijer, L. H. H., Saha, B. & Merkx, M. Nucleic acid detection using BRET-beacons based on bioluminescent protein-DNA hybrids. Chem. Commun. 53, 2862-2865 (2017)). Also, intercalating dyes have been used in combination with bioluminescent proteins, in which a luciferase was fused to a DNA-targeting zinc finger protein (Yoshida et al., Anal. Chem. 2013, 85, 13, 6485-6490). Upon the binding of the zinc finger to target dsDNA, the intercalating dye and luciferase protein are brought into proximity, leading to BRET from the luciferase to the dye. Unlike the intercalating dyes in qPCR, both these approaches focus on the specific detection of DNA and require chemical synthesis of new probes for every new target DNA.
To improve the sensitivity of point-of-care diagnostic applications, bioluminescence has also been combined with isothermal amplification of the target nucleic acid. The ‘Bioluminescent Assay in Real Time’ (BART) relies on LAMP amplification of target DNA, and enzymes that consume or convert one of the by-products of DNA polymerization to generate light (Gandelman, O. A. et al. Novel bioluminescent quantitative detection of nucleic acid amplification in real-time. PLoS One 5, (2010)). While this method has shown to be able to detect single copies of DNA, it suffers from auto-inhibition, which makes the output signal time-dependent and difficult to interpret.
Furthermore, detection of specific DNA sequences has been explored in combination with isothermal amplification through split-luciferases conjugated to single-stranded DNA (ssDNA) (Chang, D., Kim, K. T., Lindberg, E. & Winssinger, N. Smartphone DNA or RNA Sensing Using Semisynthetic Luciferase-Based Logic Device. ACS Sensors 5, 807-813 (2020)). Here, repeating target sequences on rolling circle amplification (RCA) amplicons are recognized by the system, causing the tandem assembly of the split luciferases, which reconstitutes NanoLuc, leading to blue emission. Similar to the molecular beacons and zinc fingers, this strategy requires chemical synthesis of new probes for every new target DNA.
These problems, among others are overcome by the invention as described in the appended claims.
Figure S2 | A) schematic overview of the conjugation process, including the single cysteine NanoLuc variants, 1-(2-aminoethyl)maleimide crosslinker and the NHS-activated intercalating dye B) reaction scheme for coupling of the maleimide-activated crosslinker to NHS-TO C) LCMS results of NHS-TO before the coupling of the crosslinker (top) and after the coupling of the crosslinker (bottom). Molecular masses are indicated at the top of the chromatogram peaks.
A readout based on bioluminescence circumvents the issue of requiring complex optical equipment based on lasers or LEDs, employing luciferase enzymes that produce light without requiring external excitation. We introduce a new class of bioluminescent sensor proteins based on a thermostable luciferase chemically connected to intercalating dyes that combine sensitive, non-specific detection of double-stranded DNA with a simple blue-to-green bioluminescent readout. Our invention thus makes it possible to perform quantitative, sensitive double-stranded DNA detection without any complex or highly specialized equipment, with a convenient optical readout that can be recorded with a simple digital camera or smartphone.
Therefore, in a first aspect is provided an intercalating dye probe for detection of double-stranded DNA, wherein the dye comprises a luminescence generating protein linked to one or more intercalating fluorescent dyes.
In a second aspect is provided a method of detecting double-stranded DNA in a solution, the method comprising: incubating the solution with the intercalating dye probe according to the first aspect of the invention and a suitable substrate for the luminescent domain; and detecting the light emitted by the intercalating fluorescent dye.
In a third aspect is provided a kit of parts comprising the intercalating dye probe according to the first aspect of the invention and a suitable substrate for the luminescent domain.
In a fourth aspect is provided the use of the intercalating dye probe according to the first aspect of the invention in a method of detecting double-stranded DNA.
The present invention sought to develop a new class of bioluminescent sensor proteins that combine sensitive, non-specific detection of DNA with a simple camera-based readout that is suitable for point-of-care diagnostics. To this end, we chemically conjugated one or more intercalating dyes to the thermostable NanoLuc luciferase, which emits blue-light bioluminescence upon the addition of a substrate. In absence of dsDNA, the intercalating dyes will be minimally fluorescent and only the blue light of NanoLuc is witnessed. In presence of dsDNA, the intercalating dyes bind to the dsDNA, enabling bioluminescent resonance energy transfer (BRET) from NanoLuc to the dye, after which green light is emitted (
Herein provided is thus a simple method for the detection of DNA without the need for specialized personnel or equipment, which can be applied in diagnosis and prevention of infectious diseases. The invention describes a novel molecular probe that consists of two parts: a light-emitting bioluminescent protein, which is directly attached to an intercalating dye. When the probe binds to DNA both parts interact causing the light that is produced to change color, e.g. from blue to green. The probe is simply added to a sample, after which the color change indicating the presence of DNA can be recorded and quantified using a simple camera or smartphone.
Therefore, in a first aspect is provided an intercalating dye probe for detection of double stranded DNA, wherein the dye comprises a luminescence generating protein linked to one or more intercalating fluorescent dyes. The luminescence generating protein may be a bioluminescent protein or an enzyme used for enhancing chemiluminescence.
When used herein, the term luciferase refers to a protein capable of creating bioluminescence in the presence of an appropriate substrate. Such protein may be a naturally occurring protein (e.g. a protein isolated from an organism exhibiting bioluminescence) or a modification or synthetic variant thereof. It is understood that the term luciferase refers to a broad variety of unrelated proteins which have in common the ability to exhibit bioluminescence (emitting light in the presence of a substrate), therefore any protein able to exhibit bioluminescence is for the purpose of the invention deemed a bioluminescent protein. When used herein the term luciferase activity refers to the ability of a protein to convert a substrate resulting in light emission (bioluminescence). Therefore, in an embodiment, the bioluminescent protein is a protein with luciferase activity, preferably selected from: nanoluc, firefly luciferase, renilla luciferase, metridia luciferase, bacterial luciferase, dinoflagellate luciferase, oplophorus luciferase, Gaussia luciferase, TurboLuc luciferase, Aluc luciferase, or catalytically active fragments thereof.
The bioluminescent protein is directly linked to the intercalating dye probe, enabling transfer of the emitted light from the bioluminescent protein to the intercalating dye, resulting in excitation and subsequent fluorescence of the dye. As the dye will only display fluorescence when intercalated in double-stranded DNA, the emission of the dye specific can be used to detect or quantify double-stranded DNA (dsDNA) as described herein below.
When used herein the term “linked” refers to a covalent bond. Methods of linking a dye to a protein are commonly known in the field. For example, the dye may be linked to a cysteine residue in the protein as described below. A cysteine may be introduced in the protein, e.g. when no suitable cysteine is available, by point mutation. It is further understood that multiple cysteines may be introduced to allow linking to multiple dyes. Preferably the cysteines are spatially separated, either by introducing them in different regions of the protein or by including a linker sequence, for example a 1 Lysine linker, a 2 Lysine linker or a 3 Lysine linker. Further, cysteines present in the protein at unsuitable locations may be removed by point mutation. Therefore, in an embodiment the protein with luciferase activity comprises an amino acid sequence as defined by any one of SEQ ID Nos 1 to 7.
Overview of Sequences Use in this Application:
The above protein sequences comprise:
The numbering for the mutations in the above sequences follows the native nanoluc sequence, thus excluding the STREP-tag and starting at the methionine at position 10 of the presented sequences.
Alternatively, the dye can be coupled to an enzyme which produces a substrate enabling chemiluminescence. For example a horseradish peroxidase may be coupled to allow catalysis of the oxidation of luminol using hydrogen peroxide. Therefore, in an embodiment the enzyme used for enhancing chemiluminescence is selected from horse radish peroxidase and alkaline phosphatase.
Suitable intercalating fluorescent dyes are known to the skilled person. In an embodiment the intercalating fluorescent dye is selected from acridine orange, thiazole orange, ethidium bromide, SYBR green I, SYBR Gold, SYBR Safe, EvaGreen, EvaRuby, PicoGreen, SYTO-9, TOTO-1, and YOYO-1. It is understood that the intercalating dye probe may comprise one or more, such as one, two, three, four, five or more intercalating fluorescent dyes. Multiple fluorescent intercalating dyes may be added to enhance DNA targeting of the probe. In an embodiment the intercalating dye probe further comprises an additional DNA-binding domain. This may advantageous to further enhancing binding or targeting of DNA.
In a second aspect the invention relates to a method of detecting double-stranded DNA in a solution, the method comprising:
As the intercalating dye can only be excited by the luminescence generating protein when intercalated in double-stranded DNA, detecting light emitted by the dye can be used to detect dsDNA. By also detecting the light emitted due to the luminescence generating protein (e.g. directly by a bioluminescent protein or indirectly by an enzyme for enhancing chemiluminescence), the amount of dsDNA can be quantified.
Therefore, in an embodiment the method is used to quantify double-stranded DNA, the method further comprising:
It is understood that the method may be performed in any type of amplification reaction for amplifying dsDNA. In an embodiment the amplification reaction is selected from: polymerase chain reaction (PCR), recombinase polymerase amplification (RPA), loop mediated isothermal amplification (LAMP), nucleic acid sequence based amplification (NASBA), strand displacement amplification (SDA), multiple displacement amplification (MDA), rolling circle amplification (RCA), ligase chain reaction (LCR), helicase dependent amplification (HDA) or ramification amplification method (RAM). In a third aspect the invention relates to a kit of parts comprising the intercalating dye probe according to the first aspect of the invention and a suitable substrate for the luminescent domain. In an embodiment the substrate is luciferin, preferably furimazine, firefly luciferin, latia (snail) luciferin, bacterial luciferin, coelenterazine, dinaflagellate luciferin, vargulin, 3-hydroxy hispidin or luminol. It is understood that luciferin is the general term for a compound that acts as the substrate for a luciferase, therefore the term luciferin when used herein refers to any suitable substrate of a luciferase as defined herein.
In a fourth aspect the invention relates to the use of the intercalating dye probe according to the first aspect of the invention in a method of detecting double-stranded DNA.
Other variations to the disclosed realizations can be understood and effected by those skilled in the art in practicing the claimed invention, from a study of the drawings, the disclosure, and the appended claims. In the claims, the word “comprising” does not exclude other elements or steps, and the indefinite article “a” or “an” does not exclude a plurality.
The pET28a vector containing DNA encoding the NanoLuc luciferase with an N-terminal Strep-tag and C-terminal hexahistidine-tag was ordered from GenScript. Site-directed mutagenesis to mutate the native cysteine to a serine (C166S) and introduce new cysteine and lysine residues was carried using the QuikChange Lightning Site-Directed Mutagenesis kit (Agilent) using specific primers according to the manufacturer's instructions. All cloning and mutagenesis results were confirmed by Sanger sequencing (BaseClear).
The plasmids encoding NanoLuc were transformed into chemically competent E. coli BL21 (DE3) and cultured in 2YT medium (16 g peptone, 5 g NaCl, 10 g yeast extract per liter) supplemented with 50 μg/mL kanamycin. At OD600=0.6, protein expression was induced using 1 mM isopropyl β-D-1-thiogalactopyramoside (IPTG) overnight at 20° C. Subsequently, cells were harvested by centrifugation and lysed using Bugbuster protein extraction reagent (Novagen), supplemented with Benzonase endonuclease (Novagen). Proteins were purified using Ni2+-NTA affinity chromatography, after which the elution fractions were exchanged to storage buffer (100 mM Tris-HCl, 150 mM NaCl, pH 8.0). Protein purity and correct mass were confirmed by SDS-PAGE and Q-ToF LC-MS, respectively. Purified proteins were stored at −80° C. until conjugation.
The amine-reactive N-hydroxysuccinimide (NHS) esters of Thiazole Orange (TO) and Acridine Orange (AO) were obtained from Biotium and each dissolved in DMSO to a final concentration of 20 mM. Subsequently, 3 equivalents of N,N-diisopropylethylamine (DIPEA) and 0.8 equivalents of 1-(2-aminoethyl)maleimide crosslinker (Sigma Aldrich) were added and incubated overnight at room temperature with continuous shaking at 450 rpm (
Before conjugating NanoLuc to the maleimide-activated dyes, the protein was first reduced by incubating with 5 mM of TCEP for 1 hour at room temperature with continuous shaking at 500 rpm and subsequently buffer exchanged to a sodium phosphate buffer (100 mM NaPi, 25 μM TCEP, pH 7.0) using a PD-10 desalting column (GE Healthcare). Then, the maleimide-activated TO and AO were both added in a 10-fold molar excess to 10 μM of reduced NanoLuc and allowed to react for 2 hours at room temperature with continuous shaking at 500 rpm. The NanoLuc-dye conjugates were purified by a PD-10 desalting column to remove excess dye and simultaneously buffer exchanged to PBS (100 mM NaPi, 150 mM NaCl, pH7.2). The coupling and purification were checked using SDS-PAGE by exciting the dye-protein conjugates with 470-nm blue light. Finally, the coupling efficiency and correct mass of the NanoLuc-dye conjugates were confirmed by Q-ToF LC-MS.
Bioluminescent assays were performed at sensor protein concentrations of 1 nM in a total volume of 20 μL in PerkinElmer flat white 384-well Optiplate. Sheared Salmon Sperm dsDNA fragments of ˜2000 bp were ordered from Thermo Fisher and diluted to a concentration range of 0.7 μM-5 mM, measured in terms of the number of base pairs. After incubation of sensor proteins and dsDNA fragments for 0.5 hours at room temperature, NanoGlo substrate (Promega, N1110) was added at a final dilution of 1:1000. Bioluminescence spectra were recorded in a plate reader (Tecan Spark 10M), recorded full spectra between 398 nm and 653 nm with a step size of 15 nm, a bandwidth of 25 nm and an integration time of 250 ms.
Two-Step SARS-CoV-2 cDNA Assays.
LAMP primers targeting the cDNA sequence of the Nucleocapsid (N)-gene of the SARS-CoV-2 virus were designed using the NEB LAMP Primer Design Tool and ordered from IDT. The sequence of the N-gene can be found in SEQ ID NO: 8. Primers were diluted to a 10× concentrated stock, containing 16 μM of inner primers, 2 μM of outer primers and 4 μM of loop primers. A plasmid containing SARS-CoV-2 cDNA sequences was obtained through the Free Genes Project and using specific primers, the nucleocapsid (N)-gene sequence was PCR amplified from this plasmid. The N-gene target DNA was serially diluted to 25× concentrated stocks ranging from 5 aM-5 pM. Positive LAMP reactions were assembled in a UV PCR cabinet by combining 1×isothermal amplification buffer (NEB), 6 mM of MgSO4 (NEB), 1.4 mM of dNTPs (NEB), 1×LAMP primer mix and 1×target DNA in a total volume of 24 μL. For the non-template control, similar conditions were used, only interchanging the target DNA for MilliQ water. Reactions were kept on ice during the full assembly process. To initiate the reactions, Bst 2.0 polymerase (8 U, NEB) was added followed by incubation at 65° C. for 35 minutes. Next, 10 μL of each LAMP reaction was combined with 10 μL of LUMID-2F sensor (2 nM in PBS buffer (pH 7.4, 0.1% (w/v) BSA, 5% DMSO)) in a PerkinElmer flat white 384-well Optiplate. For a negative control, the LAMP reaction was substituted for PBS buffer. After incubation for 30 minutes at room temperature, NanoGlo substrate (Promega, N1110) was added at a final dilution of 1:1000. Luminescence spectra were recorded in a plate reader (Tecan Spark 10M) between 398 nm and 653 nm with a step size of 15 nm, a bandwidth of 25 nm and an integration time of 100 ms. The green/blue ratio was calculated by dividing bioluminescent emission at 533 nm by emission at 458 nm. The luminescence signal was also recorded using a smartphone (Xiaomi mi 9 lite) camera through a hole in a Styrofoam box to exclude the surrounding light. Photographs were taken with an exposure time of 32 s, and ISO value of 3200.
One-Pot SARS-CoV-2 cDNA Assays.
LAMP reaction were assembled as described in the two-step assay, but with the addition of 1 μL of LUMID-2F sensor (25 nM in PBS buffer (pH 7.4, 0.1% (w/v) BSA, 5% DMSO)) and 1 μL of NanoGlo substrate (1:40 dilution). To initiate the reactions, Bst 2.0 polymerase (8 U, NEB) was added followed by incubation at 65° C. for 35 minutes. Real-time Luminescence was monitored using a digital camera (Sony DSC-RX100) through a hole in a dark Styrofoam box containing a heating plate to maintain the reaction temperature. After incubation, reactions were transferred to room temperature and allowed to cool down for 5 minutes before recording the Luminescence signal. Luminescence spectra were recorded in a plate reader (Tecan Spark 10M) between 398 nm and 653 nm with a step size of 15 nm, a bandwidth of 25 nm and an integration time of 100 ms. The green/blue ratio was calculated by dividing bioluminescent emission at 533 nm by emission at 458 nm. The luminescence signal was also recorded using the set up for the real-time Luminescence monitoring. Photographs were taken with an exposure time of 30 s, and ISO value of 6400.
The synthesis of the luciferase-intercalating dye probes was performed by coupling single-cysteine NanoLuc variants through a hetero-bifunctional 1-(2-aminoethyl)maleimide crosslinker to the NHS-activated form of the intercalating dyes Thiazole Orange (TO) or Acridine Orange (AO). TO was selected based on its large increase in fluorescence (>3000-fold) upon complexation with dsDNA, appropriate spectral overlap with NanoLuc (em. Nanoluc 460 nm, ex. TO 514 nm), and the commercial availability of an NHS-activated form. AO is an alternative intercalating dye that has been used as a probe to discriminate between double-stranded and single-stranded nucleic acids. Although AO is already fluorescent in solution and has a low intrinsic increase in fluorescence upon dsDNA binding, its strong intrinsic fluorescence was exploited to analyze the conjugation procedure. To allow for site-specific conjugation, single cysteine mutations were incorporated in the flexible loop region (D148) and C-terminus (G182) of NanoLuc, which are known to be suitable positions for conjugation without interfering with NanoLuc's bioluminescent properties. A hexahistidine-tag at the C-terminus was included to facilitate the purification of the single-cysteine NanoLuc mutants (the DNA and amino acid sequences and a list of protein mutants can be found in the Table above). The 1-(2-aminoethyl)maleimide crosslinker was first conjugated to the NHS-activated intercalating dyes, after which the reaction product was coupled to NanoLuc (
In order to test the analytical performance of NanoLuc-Thiazole Orange probes towards dsDNA, bioluminescence titrations with dsDNA were performed (
A promising engineering strategy to increase the overall affinity of the probes is to introduce multivalency within the current system by incorporating multiple dyes. The development of a dimeric Thiazole Orange dye (TOTO) has been shown to increase the affinity to dsDNA about three orders of magnitude compared to the monomeric variant13. Similarly, small peptides containing two Acridine Orange dyes separated by two lysine residues that provide additional, electrostatic interactions with the dsDNA, were shown to increase the dye's affinity by two to three orders of magnitude14. To apply the concept of multiple dyes with a positively charged linker to our probes, a second intercalating dye was incorporated in close proximity to the first intercalating dye at the C-terminus of Nanoluc (C180), separated by lysine residues. The amount of lysines was varied from one to three in order to find the optimal distance the dyes to bind and intercalate into the dsDNA, and glycine residues were incorporated as a control to confirm the necessity of the positive charges (
Bioluminescence titration with dsDNA revealed that the double-lysine linker responded with the highest affinity and highest dynamic range to the dsDNA (
Next, 2 cysteines separated by the best-performing 2-lysine linker were incorporated at the C-terminus and flexible loop region of NanoLuc (NanoLuc-2×TO,
In order to test the analytical performance of the NanoLuc-2×TO sensors towards dsDNA, again bioluminescence titrations with dsDNA were performed (
Interestingly, the full emission spectra reveal a positive correlation between the total emission intensity and the amount of dsDNA, which could also been seen by differences in brightness in a digital camera picture (
We also assessed the sensor performance when a third dye, separated by a 2-lysine linker, was added to the C-terminus of NanoLuc (NanoLuc-3×TO,
The present invention describes a generic bioluminescent sensor for dsDNA detection based on the coupling of one or more intercalating dyes to a light-emitting luciferase protein. Combining multivalent DNA binding of more than one dye per probe and the use of short positively charged lysine linkers between dyes resulted in high-affinity DNA detection probes with a simple bioluminescent readout. Results show that dsDNA could be detected with a ˜μM affinity (measured in base pairs) and a 4 to 9-fold change in BRET ratio. In context, most amplification strategies generate dsDNA fragments of 100-200 bp, which suggest that the sensors developed here are already capable of detecting such fragments in the low-nM range.
The present invention is envisioned to be used for the detection of viral DNA or RNA in patient samples such as blood and saliva, using rhinoviruses causing the common cold or the highly relevant and disruptive SARS-CoV-2 virus. To this end, the herein described bioluminescent intercalating proteins could be combined with amplification techniques (e.g. RPA or LAMP), which provide a straightforward method to perform an initial pre-amplification step in order to increase the sensitivity of the assay required for the detection of DNA directly in patient samples. Because of the thermal stability of NanoLuc, we expect that the NanoLuc-TO conjugates can be used to monitor the progression of RPA (T=42° C.) in a one-pot reaction in real-time. It is further envisioned that the present invention further increases the affinity of the luciferase-TO conjugates for dsDNA by combining bivalent TO labeling at the loop position with bivalent labeling at the C-terminus. Further envisioned are fusions of the NanoLuc domain to a generic dsDNA binding domain to further increase sensitivity.
In context, dsDNA fragments are typically 100-200 base pairs long, suggesting that the sensors developed here are capable of detecting such fragments in the low-nanomolar range. Since most diagnostic applications, such as viral nucleic acid detection, require attomolar sensitivity, we next explored combining our bioluminescent probes with different isothermal amplification steps to develop a simple and sensitive assay platform that can be used at the point of care. Of the methods explored, LAMP was found most suitable due to the high dsDNA yield with minimal non-specific amplification, which is essential to avoid large background signals when employing a non-specific read-out. Motivated by the ongoing COVID-19 pandemic, LAMP reactions were designed to target the complementary DNA (cDNA) sequence of the nucleocapsid (N)-gene of the SARS-CoV-2 virus, exploring the feasibility of the LUMID probes for a rapid, point-of-care test for viral detection.
We first developed a two-step assay in which serially diluted SARS-CoV-2 cDNA was amplified using LAMP and subsequently combined with LUMID-2F to facilitate bioluminescent detection (
Although this primer-related background signal decreases the assay's dynamic range, the observed change in emission ratio is robust and comparable to BRET-based sensor's in general. These results illustrate that our LUMID sensors can be combined with LAMP to create a sensitive nucleic acid assay platform in which results can be obtained in approximately 1 hour using simple, smartphone-based detection.
We next assessed whether we could combine all assay components in a single tube, demonstrating the viability of this platform as a single-step point-of-care diagnostic tool. This approach would not only simplify the experimental procedure, but also reduce the risk at false-positives that may arise as a result of cross-contamination during post-amplification reaction transfer. We therefore combined the LAMP reaction components with serially diluted SARS-CoV-2 cDNA, LUMID-2F sensor (1 nM) and NanoLuc substrate (1000× dilution) in a single tube, before incubation for 35 minutes at 65° C. (
Number | Date | Country | Kind |
---|---|---|---|
2029944 | Nov 2021 | NL | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/NL2022/050685 | 11/28/2022 | WO |